欧美一区视频在线,欧美黑人又粗又大的性格特点,精品国产福利在线

新聞中心

News Center

當前位置:首頁新聞中心Biomedica Gruppe公司

Biomedica Gruppe公司

更新時間:2017-09-12點擊次數:2038

Biomedica Gruppe公司

公司簡介

  • 1978年, 成立Biomedica Gruppe公司,分設醫療器械和體外診斷部,在歐洲和美國有13個子公司。
  • 公司總部位于奧地利首都維也納,員工數超過250人。
  • 1988年成立免疫測定研究部門。開發和生產基于ELISA檢測的,臨床研究相關的檢測標記物。
  • 2009生物標記研究組從原免疫測定部門的分離出來,并注冊了新的公司(BDF),繼續研究開發創新性的ELISA檢測生物標記物。(例如:骨代謝或心血管疾病)
  • 至今Biomedica公司在心血管檢測、骨代謝檢測領域開發了一系列檢測試劑盒,并在世界各地設有代理商,銷售網絡遍布。

臨床前和臨床研究的ELISA檢測生物標記物

骨代謝

心血管疾病

氧化應激

Osteoprotegerin

BNP Fragment*

MDA-oxLDL*

Free soluble Rankl

proANP

Peroxides

Dickkopf-1*

NT-proCNP

Autoantibodies against oxLDL

Sclerostin*

Big Endothelin

 

Cathepsin K*

Endothelin

 

 

Endostatin*

 

骨質酥松癥、關節炎、骨代謝紊亂、腫瘤誘導的骨病

冠狀動脈疾病、shen病、癌癥

冠狀動脈疾病、shen病、動脈硬化

* 于科研應用 ,其他的已在歐洲用于臨床診斷

 

 

 

 

 

 

ELISA 定量檢測試劑盒

骨代謝

應用

Osteoprotegerin OPG

心血管疾病評價的標記物

Free soluble Rankl (sRankl)

可控制孕酮水平變化導致的乳腺癌及抑制骨腫瘤細胞的進一步惡化。

Dickkopf-1(DKK-1)

減輕病人對骨髓瘤治療的MM應答

Sclerostin

Sclerostin 抗體治療,促進骨質形成。

Cathepsin K

 

心血管疾病

應用

BNP Fragment8-29

心血管疾病預后治療檢測的標記物

proANP1-98

抗腫瘤治療的新靶點,可預測慢性心衰竭的患者的生存率。

NT-proCNP

可預測創傷引起的敗血癥發病率

Big Endothelin1-38

ET-A受體拮抗劑,用于改善冠脈內皮功能。

ET-B 受體,腫瘤免疫治療的靶點

Endothelin1-21

Endostatin

內源性的血管生成抑制劑,是慢性shen臟病人微血管檢測的可能的標記物

氧化應激

應用

MDA-oxLDLMDA-oxLDL

與代謝綜合征和冠心病風險檢測相關,是急性心肌梗死的影響因子。

Autoantibodies against oxLDL(oLAB)

評價藥物對氧化低密度脂蛋白自身抗體產生的相關效應。

Peroxides

 

 

 

 

 

 

 

 

骨代謝系列產品

 

骨代謝標記物

在絕經婦女、骨固定引起的骨質流失患者、多重骨髓瘤患者Sclerostin水平顯著升高。經甲狀旁腺素(PTH)和雌性激素持續治療后,血清Sclerostin水平降低。隨著SclerostinDKK-1中和抗體的開發研究,有望對于骨代謝疾病治療,獲得新進展。

Sclerostin ELISA Kit (BI-20492)

檢測方法

夾心ELISAHRP/TMB顯色系統

樣本

血清、血漿

樣本量

20ul/test12 x8 test

檢測范圍

0-240pmol/L

靈敏度

2.6pmol/L

孵育時間

過夜/1h/30min

DKK-1Sclerostinswnt信號通路的有效的抑制劑,且在成骨細胞的分化過程中發揮重要作用。研究表明,骨形成減少、多發性骨髓瘤或由乳腺癌、前列腺癌、肺癌或關節炎引起的骨轉移,都可導致DKK-1水平升高,

Dickkopf-1 ELISA kit (BI-20413)

檢測方法

夾心ELISAHRP/TMB 顯色系統

樣本

血清、細胞培養上清

樣本量

20ul/test12 x8 test

檢測范圍

0-160pmol/l

靈敏度

1.7pmol/L

孵育時間

2h/1h/30min

sRankl 是(NF-KB配體的可溶性受體激活因子,是成熟破骨細胞形成的主要刺激因子,對于破骨細胞的存活具有重要作用。Rankl 激活位于成骨細胞及樹突細胞其特異性受體Rank

sRankl ELISA kit (BI-20452)

檢測方法

夾心ELISA,檢測系統:AP/ NADPH

樣本

血清、血漿、細胞培養上清

樣本量

100ul/test12 x8 test

檢測范圍

0-2pmol/L

靈敏度

0.02pmol/L

孵育時間

過夜/1h/30min

OPGRankl的可溶性分泌受體,可抑制破骨細胞的發育。

Osteoprotegerin(OPG) ELISA kit (BI-20403)

檢測方法

夾心ELISA,檢測系統:HRP/TMB

樣本

血清、血漿

樣本量

20ul/test12 x8 test

檢測范圍

0-20pmol/L

靈敏度

0.07 pmol/L

孵育時間

3h/1h/30min

Cathepsin K 是破骨細胞活化、重吸收中大量表達的合成蛋白。Cathepsin K含量的升高,反映了sRankl 激活破骨細胞的能力。

Cathepsin K ELSIA kit (BI-20432)

檢測方法

夾心ELISA,檢測系統:HRP/TMB

樣本

血清、細胞培養上清

樣本量

50ul/test12 x8 test

檢測范圍

0-300pmol/l

靈敏度

1.1pmol/L

孵育時間

過夜/30min

 

Sclerostin 是由骨細胞產生的wnt 信號通路中的一種抑制劑。

SOST ELISA 檢測試劑盒

應用領域
1shen病檢測

2)腫瘤誘導的骨病

3)代謝病治療的療效監測,例如:甲狀旁腺治療的監測。

4)風濕性關節炎

5)骨質疏松癥

 產品特點

  1. 充分驗證可用于人血清、血漿樣本檢測。(尿標本檢測參照對應的protocol
  2. 樣本量小,只需20ul
  3. 高靈敏度-正常值介于標準曲線,標準品2和標準品3值之間。
  4. 6個校準品+1個對照(標準品和對照均為人血清基質,檢測結果相關性更好)
  5. 即用型檢測試劑盒

試劑盒特點:

1)檢測方法:夾心ELISA,HRP/TMB顯色系統

2)樣本類型:血清、血漿(EDTA或肝素抗凝)、尿樣(參照對應的protocol

3)樣品量:20ul/test

4)標準品范圍:0-240 pmol/L

5)檢測靈敏度:2.6pmol/L

6)孵育條件:過夜/1小時/30分鐘(室溫)

7)單位轉換1pg/ml=0.044pmol

 

 

參考文獻

試驗設計

結論

Association of sclerostin levels with the severity of aortic valve calcification. Koos R et al., JACC ; 2011; 57, 14

心臟主動脈瓣硬化患者

樣本:115

與正常人群相比心臟主動脈瓣硬化(AVC)患者,sclerostin水平顯著升高。AVC疾病的嚴重程度與sclerostin血清水平相關。

Sclerostin and Dickkopf-1 in Renal Osteodystrophy. Cejka D et al., Clin J Am Soc  Nephrol; 2011; 6: 877-882

慢性shen臟病患者(CKD-5D

樣本:60

針對高轉換性骨代謝的CKD-5D病人除了檢測IPTH外,還可檢測Sclerostin作為評價指標。

Sclerostin serum levels correlate positively with bone mineral density and microarchitecture in haemo-dialysis patients. Cejka D et al.,  Nephrol DiaTransplant; 2012; 27: 226-230

血透患者

樣本:76

對照樣本:45

血透患者的sclerostin水平,顯著高于對照樣本。骨密度(BMD)與血清sclerostin水平呈正相關。

Circulating Sclerostin Levels and Bone Turnover in Type 1 and Type 2 Diabetes. Gennari L et al., J Clin Endo Metab; 2012; 97: 1737-1744

II型糖尿病患者(DM2):40

I型糖尿病患者(DM1):43

對照樣本:83

研究表明,DM2患者sclerostin水平升高。此外,由PTH 抑制轉錄sclerostin可能在DM1DM2病人減弱。

Circulating sclerostin and Dickkopf-1 (DKK1) in predialysis chronic kidney disease (CKD): relation-ship with bone density and arterial stiffness. Thambiah S et al., Calcif Tissue Int; 2012; 90(6): 473-480

慢性shen臟疾病(CKD3B期患者32

慢性shen臟疾病(CKD4期患者:45

Sclerostin水平與年齡成正相關。男性Sclerostin水平要高于女性。shen小球濾過率(GFR)與Sclerostin水平呈負相關。骨密度(BMD)與血清sclerostin水平呈正相關。Wnt 信號通路可能在代謝紊亂疾病中發揮重要作用。

 

 

 

 

 

2013 ISN 研討會會議論文(骨病與shen病)

試驗設計

結論

Bone density and arterial stiffness are related to circulating sclerostin and Dickkopf-1 (DKK1) in pre-dialysis chronic kidney disease (CKD) patients. Goldsmith D et al.,  Poster # 15

血透前患者:

CKD 3B期和4期患者:77

 

該研究為:Wnt 信號通路抑制劑(Sclerostin DKK-1)在確定骨骼和血管功能及慢性shen臟病人(CKD)結構中發揮重要的作用,提供有力證據。

Circulating sclerostin levels and vascular calcification in chronic kidney disease: A

complex relationship. Claes KJ et al.,Poster # 91

無機代謝縱向研究:154

AC患者表達高水平的sclerostin。反之,sclerostin較低。后續的臨床和實驗研究需進一步闡明sclerostin是否在保護血管鈣化中起到重要作用。

Sclerostin and DKK-1 levels in pre-dialysis CKD patients. Behts G et al.;  Poster # 89

觀測性研究:

149病人(慢性shen病患者CKD 1-5期,男性:81例,60±16歲,22位糖尿病患者)

 

隨著shen病嚴重程度,sclerostin(非DKK-1)水平升高。

Low PTH and high circulating sclerostin levels are independently associated with low bone specific alkaline phosphatase levels in hemodialysis patients. Viaene L et al., Poster # 90

血透病人:100

Sclerostin水平的升高是糖尿病患者、shen功能不全(RRF)、急性胰腺炎(BSAP)患者的獨立的風險因素。Sclerostin水平的高表達及PTH 的低表達與BSAP相關,反映了低水平的骨質形成。

 

 

 

 

 

 

 

 

參考文獻:Sclerostinshen病、糖尿病、心臟主動脈瓣硬化患者的關系。

*作者及參考文獻

疾病

研究群體/試驗設計

主要結論

Sclerostin: another bone-related protein related to all-cause mortality in haem dialysis? Viaene L et al., Nephrol Dial Transplant, 2013; 10.1093/ndt/gft039

 shen

血透患者(觀察隨后637天個體的生存率),100

血透患者Sclerostin水平的升高與提高生存率相關。

The Relation between Renal Function and Serum Sclerostin in Adult Patients with CKD. Pelletier S et al., Clin J Am Soc Nephrol, 2013; 8: 819-823

慢性shen病患者(CKD):90

CKD III 期:Sclerostin水平開始升高。

Sclerostin and DKK-1 levels in pre-dialyisis CKD patients. Behets G et al., Nephrol Dial Transplant, 2012; 27: ii36-ii37

慢性shen病患者(橫向觀察性研究):149

隨著shen病嚴重程度,sclerostin(非DKK-1)水平升高。

Sclerostin serum levels correlate positively with bone mineral density and microarchitecture in haemodialysis patients. Cejka D et al., Nephrol Dial Trans-plant, 2012; 27: 226-230

血透患者(橫向研究):76

血透患者的sclerostin水平,顯著高于對照樣本。

Sclerostin Levels Associated with Inhibition of the Wnt/β-Catenin Signaling and Reduced Bone Turnover in Type 2 Diabetes Mellitus. Gaudio A et al., J Clin Endocrinol Metab, 2012; 97: 3744–3750

糖尿病

絕經婦女II型糖尿病患者(橫向研究):40

與之前研究結果一致,II型糖尿病患者sclerostin水平高于對照樣本及骨轉換標記物水平低于對照樣本。

Circulating Sclerostin Levels and Bone Turnover in Type 1 and Type 2 Diabetes.

Gennari L et al., J Clin Endo Metab, 2012; 97: 1737-1744

I型和II型糖尿病患者(橫向研究)

DM143   DM240

研究表明:II型糖尿病患者sclerostin水平升高。

Association of Sclerostin levels with the severity of aortic valve calcification. Koos et al., JACC, 2011; 57, 14

心臟主動脈瓣硬化

主動脈瓣患者(橫向研究):115

與正常健康對照樣本群體比較,AVC患者sclerostin水平升高。

Serum Sclerostin levels are associated with aortic valve calcification in prevalent ha-emodialysis patients. Türkvatan A et al., Nephrol Dial Transplant, 2013; 28: i19–i21

血透患者:101

AVC患者sclerostin血清水平顯著高于未鈣化的AVC患者相比,。

Circulating Sclerostin and Dickkopf-1 (DKK1) in predialysis chronic kidney disease (CKD): relationship with bone density and arterial stiffness. Thambiah S et al., Calcif Tissue Int, 2012; 90(6): 473-480

動脈硬化

慢性shen病患者CKD 3BQ期和4期:77

shen小球濾過率(GFR)與Sclerostin水平呈負相關。Wnt 信號通路可能在代謝紊亂疾病中發揮重要作用。

 

 

 

 

DKK-1檢測試劑盒

直接測定,無需樣本稀釋

貨號:BI-20413  

DKK-1 Wnt 信號通路的抑制劑

BI-20413BI-20412對比

檢測特點

BI-20413

BI-20412

孵育時間

2h/1h/30min

孵育過夜

樣品處理

直接測定

需要1:4稀釋

標準品范圍

0-160pmol/L

0-50pmol/L

應用領域

  1. 骨代謝疾病
  2. Wnt信號通路

產品優勢:

  1. 當日即可檢測
  2. 直接測定,不許樣品稀釋。
  3. 樣本需求量少,只需:20ul
  4. 標準品范圍廣
  5. 充分證實可用于人血清樣本檢測
  6. 6個標準品+1個對照(均為血清基質)

7)操作流程簡單

試劑盒特點:

1)檢測方法:夾心ELISAHRP/TMB顯色系統

2)樣本類型:血清

3)樣品量:20ul/test

4)標準品范圍:0-160 pmol/L

5)檢測靈敏度:1.7pmol/L

6)孵育條件:2h/1h/30min

 

 

參考文獻

1

Comparative Effect of Zoledronic Acid Versus Denosumab on Serum Sclerostin

and Dickkopf-1 Levels of Naive Postmenopausal Women With Low Bone Mass: A

Randomized, Head-to-Head Clinical Trial. Athanasios D. Anastasilakis, et al.

J. Clin. Endocrinol. Metab., Aug 2013; 98: 3206 - 3212.

2

Elevated Serum Dickopff-1 Levels Increase Risk of Hip and Vertebral Fracture in Older Caucasian Women. Aarthi Arasu,et al. Endocr. Rev., Jun 2013; 34: SAT-224.

3

Genetic studies on components of the Wnt signalling pathway and the severity of joint destruction in rheumatoid arthritis. Diederik P C de Rooy,et al. Ann Rheum Dis, May 2013; 72: 769 - 775.

4

High dickkopf-1 levels in sera and leukocytes from children with 21-

hydroxylase deficiency on chronic glucocorticoid treatment. Giacomina Brunetti,et al. Am J Physiol Endocrinol Metab, Mar 2013; 304: E546 - E554.

5

Sclerostin and DKK1 in postmenopausal osteoporosis treated with denosumab. D Gatti,et al. J Bone Miner Res, Nov 2012; 27(11): 2259-63. 

6

Sclerostin Levels Associated with Inhibition of the Wnt/β-Catenin Signaling and Reduced Bone Turnover in Type 2 Diabetes Mellitus. Agostino Gaudio,et al. J. Clin. Endocrinol. Metab., Oct 2012; 97: 3744 - 3750.

7

Serum Osteoprotegerin, RANKL, and Dkk-1 Levels in Adults with Langerhans

Cell Histiocytosis. Polyzois Makras,et al. J. Clin. Endocrinol. Metab., Apr 2012; 97: E618 - E621

8

High level of functional dickkopf-1 predicts protection from syndesmophyte

formation in patients with ankylosing spondylitis. Gisela Ruiz Heiland,et al. Ann Rheum Dis, Apr 2012; 71: 572 - 574. 

9

Assessment of circulating Dickkopf-1 with a new two-site immunoassay in

healthy subjects and women with breast cancer and bone metastases. N Voorzanger-Rousselot, et al. Calcif Tissue Int, May 1, 2009; 84(5): 348-354

10

Circulating Dickkopf-1 and Radiological Progression in Patients with Early

Rheumatoid Arthritis Treated with Etanercept. Patrick Garnero,et al. J Rheumatol, Oct 2008.

11

Increased Sclerostin Serum Levels Associated with Bone Formation and Resorption Markers in Patients with Immobilization-Induced Bone Loss. Agostino Gaudio,et al. J. Clin. Endocrinol. Metab., May 2010; 95: 2248 - 2253.

12

High Serum Sclerostin Correlates with Advanced Stage, Increased Bone

Resorption, Reduced Osteoblast Function, and Poor Survival in Newly-Diagnosed Patients with Multiple Myeloma. Evangelos Terpos,et al. Blood (ASH Annual Meeting Abstracts), Nov 2009; 114: 425.

13

The Effect of Zoledronic Acid on Serum Dickkopf-1, Osteoprotegerin, and RANKL

in Patients with Paget's Disease of Bone. S A Polyzos, et al. Horm Metab Res, Aug 2009 

14

Glucocorticoids Attenuate the Stimulatory Effect on Bone Formation by

Bortezomib. Thomas Lund,et al. Blood (ASH Annual Meeting Abstracts), Nov 2008; 112: 5183. 

 

 

Endostain檢測試劑盒

定量檢測人血清中Endostain

貨號:BI-20742

Endostain 血管生成抑制劑

應用領域:

1微血管損傷

2)慢性shen病(CKD)

3) 局部貧血

產品優勢:

  1. 檢測范圍寬
  2. 6個即用型校準品
  3. 可當日檢測,半小時內出結果
  4. 只需5ul樣本
  5. 嚴格按照ICH要求,證實可用于人樣本檢測
  6. 可靠、重復性好的實驗結果:批內<6%,批間<5%

試劑盒特點:

1)檢測方法:夾心ELISA96孔,HRP/TMB顯色系統

2)樣本類型:血清、血漿(檸檬酸鹽抗凝、EDTA抗凝、肝素抗凝)、尿(參照對應的protocol

3)樣品量:5ul

4)標準品范圍:0-80 nmol/L(0-1600ng/ml)

5)檢測靈敏度:0.02nmol/L(0+3SD)

6)孵育條件:2h/1h/30min,室溫

7)單位轉換:1 ng/ml = 0.05 nmol/l (MW = 20 kDa) 

8)特異性:人樣本與其他種屬無交叉反應

 

參考文獻

試驗設計

結論

Elevated plasma levels of endostatin are associated with chronic kidney disease. J Chen, LL Hamm, et al.Am J Nephrol, Jan 2012; 35(4): 335-340

CKD患者:201

對照群體:201

血漿Endostain的升高,與CKD患者高度相關。進一步研究及臨床實驗已批準驗證Endostain與CKD發病風險之間的關系及研究針對Endostain的新的干預措施,以減少CKD的發病風險。

Early-onset coronary artery disease after pediatric kidney transplantation: implicatingthe angiogenesi inhibitor, endostatin. CW Iqbal,et al. Am Surg, Jun 2011; 77(6): 731-735

接受shen移植者:12

接受肝移植者:8

與肝移植者及健康對照個體相比,shen移植者Endostain水平升高。Endostain在shen移植后引起的動脈硬化疾病中發揮重要作用,且Endostain可能作為動脈硬化疾病檢測的生物標記物。

Immobilized kidney 28-kDa endostatin-related (KES28kDa) fragment

promotes endothelial cell survival.MH Bellini, et al.

Am J Nephrol, Jan 2010; 31(3): 255-261

可溶性和固定化的Endostatin 對細胞活性影響。

研究表明:由急性shen損傷(AKI)引起的局部合成28KD相關的Endostain片段,對于內皮細胞的存活,發揮重要作用。

Endostatin and angiostatin are increased in diabetic patients with coronary artery disease and associated with impaired coronary collateral formation. Neel R. Sodha, et al.Am J Physiol Heart Circ Physiol, Feb 2009; 296: H428-H434

經動脈搭橋術手術病人的心肌組織

(非糖尿病例:11 II型糖尿病:10例)

研究表明:在促血管新生治療中,Endostain是潛在的治療靶點,且糖尿病患者可見血管損傷。

A defective angiogenesis in chronic kidney disease.N Futrakul,et al. Jan 2008; 30(2): 215-217

通過研究血管生成因子、Endostain、VEGF、抗血管生成因子之間的平衡,來反映血管損傷程度。

慢性shen(CKD)患者Endostain及CEC非正常升高,而VEGF表現為缺乏。

 

 

 

NT-proBNP ELISA Kit

為什么要檢測NT-proBNP

NT-proBNP proBNP分解后的76氨基酸片段。proBNP是心臟為彌補收縮無力而增大時,心壁被拉伸時由心臟釋放到血液中的化學物質。一旦從心臟釋放到血液中,proBNP就會分割為NT-proBNPBNP。由于NT-proBNP的半衰期為120min,相比之下,BNP的半衰期僅20min。所以NT-proBNP可追蹤的時間可達24hBNPzui多可監測的時間為1h。因此,檢測血清/血漿中的NT-proBNP穩定性更好,檢測結果更可靠,是有效的心衰檢測工具。

應用領域:

  1. 心臟衰竭、急性心肌梗死(左心室功能不全)
  2. shen衰竭
  3. 肥胖癥和糖尿病
  4. 各種形式的繼發性高血壓
  5. 心衰患者的療效監測

產品優勢:

  1. 性價比高
  2. 可用于每個實驗室或開放實驗室
  3. CE 標志-可用于臨床診斷
  4. 簡單-傳統96孔板
  5. 動態檢測范圍廣-可用于早期心衰檢測

試劑盒特點:

檢測方法:夾心ELISAHRP/TMB顯色,12x8 板條

樣本類型:血清

樣品量:50ul/test

標準品范圍:0-640 pmol/L

檢測靈敏度:3pmol/L

孵育條件:3h/30min

單位換算:1pmol/L=8.475pg/ml

 

 

 

1

Infliximab Treatment Increases Left Ventricular Ejection Fraction in Patients with Rheumatoid Arthritis: Assessment of Heart Function by Echocardiography, Endothelin 1, Interleukin 6, and NT-pro Brain Natriuretic Peptide. PRZEMYSLAW J,et al. J Rheumatol, Apr 2012; 39: 701 - 706.

2

Left Ventricular Function Impairment in Patients With Normal-Weight Obesity:

Contribution of Abdominal Fat Deposition, Profibrotic State, Reduced Insulin

Sensitivity, and Proinflammatory Activation. Wojciech Kosmala,et al. Circ Cardiovasc Imaging, May 2012; 5: 349 - 356.

3

Prognostic value of left atrial expansion index and exercise-induced change in atrial natriuretic peptide as long-term predictors of atrial fibrillation recurrence..Malini Govindan,et al. Europace, Sep 2012; 14: 1302 - 1310.

4

Osteopontin-mediated myocardial fibrosis in heart failure: a role for lysyl

oxidase? Begoña López,et al. Cardiovasc Res, Jul 2013; 99: 111 - 120. 

5

High-sensitivity troponin assay improves prediction of cardiovascular risk in

patients with cerebral ischaemia. Raoul Stahrenberg,et al. J. Neurol. Neurosurg. Psychiatry, May 2013; 84: 479 - 487.

6

Translational phases of evidence in a prognostic biomarker: a systematic review and meta-analysis of natriuretic peptides and the prognosis of stable coronary disease. Shailen Sutaria,et al. Heart, Apr 2012; 98: 615 - 622. 

7

Prognostic impact of body mass index in patients undergoing coronary artery

bypass surgery. Shih-Hsien Sung,et al. Heart, Apr 2011; 97: 648 - 654.

8

Troponin T, N-terminal pro natriuretic peptide and a patent ductus arteriosus

scoring system predict death before discharge or neurodevelopmental outcome at 2 years in preterm infants. Afif F EL-Khuffash,et al. Arch. Dis. Child. Fetal Neonatal Ed., Mar 2011; 96: F133 - F137. 

9

Multidimensional assessment of older people with asthma and COPD: clinical

management and health status. Vanessa M. McDonald,et al. Age Ageing, Jan 2011; 40: 42 – 49

10

Diagnostic value of NT-proBNP in identifying aortic stenosis patients with heart failure. C Wu,et al. Zhonghua Xin Xue Guan Bing Za Zhi, Jul 2010; 38(7): 579-83.

11

Pulmonary arterial hypertension in rheumatic mitral stenosis: does it affect right

ventricular function and outcome after mitral valve replacement? Shantanu Pande,et al. Interact CardioVasc Thorac Surg, Sep 2009; 9: 421 - 425

12

Pulmonary arterial hypertension in rheumatic mitral stenosis: does it affect right

ventricular function and outcome after mitral valve replacement? Shantanu Pande,et al. Interactive CardioVascular and Thoracic Surgery, Sep 2009; 9: 421 - 425.

13

Effect of piboserod, a 5-HT4 serotonin receptor antagonist, on left ventricular

function in patients with symptomatic heart failure. John K. Kjekshus,et al. Eur J Heart Fail, Aug 2009; 11: 771 – 778

14

Prevalence of Left Ventricular Diastolic Dysfunction in a General Population. Tatiana Kuznetsova,et al. Circ Heart Fail, Mar 2009; 2: 105 - 112.

參考文獻:

BNP Fragment ELISA kit –new protocol

定量檢測人BNP

貨號:BI-20852W

BNP與尿鈉排泄、多尿、血管舒張、shen素抑制、醛固酮分泌等生物功能密切相關,在心血管功能穩定中發揮重要的調節作用。

應用領域:
1心臟衰竭

2)心肌梗死

3)肥胖、糖尿病

4shen衰竭

5)各種形式的繼發性高血壓

產品優勢:

1)無需提取

2直接檢測

3)樣品需求量少

4可用于每個實驗室或開放實驗室

5)被測物穩定

6)實驗結果重復性、可靠性高

產品特點:

檢測方法:競爭ELISAHRP/TMB顯色

樣本類型:血清、血漿

樣品量:30ul/test

標準品范圍:0-6400 pmol/L

檢測靈敏度:171pmol/L=410pg/ml, at 95% B/B0 

孵育條件:過夜/20min

 

 

 

參考文獻:

1

Thirty years of the heart as an endocrine organ: physiological role and clinical utility of cardiac natriuretic hormones. Clerico A et al., Am J Physiol Heart Circ Physiol 2011; 301: H12-H20

2

Comparison of Pleural Fluid N-Terminal Pro-Brain Natriuretic Peptide and Brain Natriuretic-32 Peptide Levels. Long AC et al., Chest 2010; 137: 1369-1374

3

N-Terminal Pro-B-Type Natriuretic Peptide as an Indicator of Possible Cardiovascular Disease in Severely Obese Individuals: Comparison with Patients in Different Stages of Heart Failure. Hermann-Arnhof K et al., Cl inical Chemistry 2005; 51:138-143

4

Natriuretic Peptides: New Players in Energy Homeostasis.  Moro C and Smith RH, Diabetes 2009; 58: 27-26

5

Risk assessment in patients with unstable angina/non-ST-elevation myocardial infarction and normal N-terminal pro-brain natriuretic peptide levels by N-terminal pro-atrial natriuretic peptide. Jarai R et al., Eur Heart J 2004; 26: 250-256

6

Natriuretic peptides: Markers or modulators of cardiac hypertrophy? Gardner DG, Trends Endocrinol Metab 2003; 14: 411-416

7

Neurohormonal risk stratification for sudden death and death owing to progressive heart failure in chronic heart failure. Berger R et al, Eur J Clin Invest 2005, 35, 24-31

8

Natriuretic peptides/cGMP/cGMP-dependent protein kinase cascades promote muscle mitochondrial biogenesis and prevent obesity. Miyashita K et al., Diabetes 2009; 58: 2880-2892

9

Processing of Pro–B-Type Natriuretic Peptide: Furin and Corin as Candidate Convertases. Semenov AG et al., Clin Chem. 2010; 56:1166-1176

 

 

 

 

 

 

 

 

 

 

 

 

 

Anti-c4d 抗體

shen移植體液調節的標記物

用于流式或發光法檢測石蠟及冰凍切片C4d補體。

C4d是抗體觸發補體通過經典途徑活化后C4的裂解產物,能穩定地結合在發生排斥的移植物內皮的表面。檢測C4d作為機體針對同種異體移植物抗體檢測的一個間接信號,大量研究表明:C4dshen移植免疫中的重要標記物,同時也是心臟、肝及其他器官移植免疫檢測的重要標記物。

檢測原理:

包被了HLA抗原的微球與被檢血清中的抗HLA抗體結合(A),形成抗原抗體復合物。加入補體后(血清取自健康非敏感人群),在微球表面激活了典型的補體級聯反應(B)。用

PE-conjugated anti human c4d 檢測結合的C4d

 

 

 

 

 

 

 

產品優勢:

  1. 用于檢測人C4d補體。
  2. 該抗體可用于發光法或用One Lambda 公司的LABScreen® Single Antigen beads流式檢測細胞內或固相結合的C4C4d片段。

試劑盒特點:

1) 檢測樣本:血清

2) 來源:兔多克隆抗體

3) 形式:50ul,PE 標記純化的IgG片段。

4應用Luminex®-檢測、流式檢測

 

 

參考文獻:

1

C4d deposition is associated with inferior kidney allograft outcome independ.of cellular rejection. Regele H. et al., Nephrol Dial Transplant. 2001, 16(10): 2058-2066.

2

Capillary C4d deposition in kidney allografts: a specific marker of alloantibody-dependent graft injury. Böhmig GA et al., J Am Soc Nephrol. 2002, 13(4): 1091-1099.

3

[C4d]FlowPRA screening—a specific assay for selective detection of complement-activating anti-HLA alloantibodies. Wahrmann M et al., Hum Immunol, 2005, 66(5): 526-534

4

Pivotal role of complement-fixing HLA alloantibodies in presensitized kidney allograft recipients. Wahrmann M et al., Am J Transplant, 2006, 6: 1033-1041.

5

In vitro detection of C4d-fixing HLA alloantibodies: associations with capillary C4d deposition in kidney allografts. Bar G et al., Am J Transplant, 2008, 8(1): 41-49

6

Antibodies, isotypes and complement in allograft rejection. Böhmig GA et al., Curr Opin Organ

Transplant, 2008, 13(4): 411-418

7

Solid phase detection of C4d-fixing HLA antibodies to predict rejection in high immunological risk kidney transplant recipients. Bar G et al., Transpl Int. 2013; 26(2): 121-130.

8

Preformed complement-activating low-level donor-specific antibody predicts early antibody-mediated rejection in renal allografts. Lawrence C et al., Transplantation 2013 Jan 27; 95(2): 341-346.

9

Modified solid-phase alloantibody detection for improved crossmatch prediction. Wahrmann M et al., Hum Immunol. 2013 Jan; 74(1): 32-40.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

全線產品:

類別

貨號

名稱

規格

骨代謝系列

BI-20492

Sclerostin (SOST) ELISA 

1 Kit

BI-20413 

DKK-1 ELISA 

1 Kit

BI-20432 

Cathepsin K ELISA Kit

1 Kit

BI-20403

OPG ELISA

1 Kit

BI-20452

sRANKL ELISA

1 Kit

心血管疾病

BI-20742 

Endostatin ELISA

1 Kit

BI-20082H

Big Endothelin-1 ELISA

1 Kit

BI-20052

Endothelin ELISA

1 Kit

BI-20872 

NT-proCNP ELISA

1 Kit

BI-20852W

BNP Fragment ELISA

1 Kit

SK-1204

NT-proBNP ELISA

1 Kit

BI-20892

proANP ELISA

1 Kit

動脈硬化

氧化應激

BI-20032

Anti-Oxidized LDL (oLAB) ELISA

1 Kit

BI-5007

OxyStat Assay (Peroxides)ELISA

1 Kit

BI-20022

MDA-oxLDL ELISA

1 Kit

傳染病

BI-21032 

Borrelia lgG ELISA

1 Kit

BI-21042

Borrelia lgM ELISA

1 Kit

BI-3501 

Rheumatoid Factor Stripper

1 Kit

細胞增殖

BI-5000

 

EZ4U Cell Proliferation Assay

 

1 Kit

抗體

BI-RC4D

Polyclonal Anti-human C4d antibody

200ul

BI-RC4D-FITC

Polyclonal Anti-human C4d FITC Antibody

100 µl

BI-RC4D-PE

Polyclonal Anti-human C4d PE Antibody

50 µl

 

 

 

 

 

 

 

 

 

 

  • 主站蜘蛛池模板: 奉节县| 龙江县| 灵武市| 绿春县| 西丰县| 丰台区| 南开区| 阳山县| 天祝| 观塘区| 济源市| 吉安县| 信宜市| 景洪市| 沧州市| 保靖县| 崇阳县| 长宁县| 边坝县| 和静县| 蓬溪县| 扶沟县| 阜平县| 鄂尔多斯市| 隆安县| 鞍山市| 忻州市| 黔西县| 鹿邑县| 拉萨市| 承德县| 红原县| 九台市| 衡南县| 嵩明县| 城固县| 碌曲县| 德格县| 临夏县| 鄯善县| 疏附县|